国家食品安全风险评估中心,欢迎您! 加入收藏 | 邮箱登录 | English
当前位置
首页 > 实验室人员 > 主要学科带头人 > 详情
站内搜索
 

人员介绍

  • 王慧
  • 重点实验室副主任

综合简介

        王慧  女,196912月生,博士,研究员、博士生导师,国家杰出青年基金获得者。

        1999年在天津医科大学/美国伯明翰阿拉巴马大学(UAB)获得医学、理学博士学位(中美联合培养)1999年至2001年在美国UAB大学从事博士后研究;之后在美国UAB大学临床药理部、药理与毒理系任讲师(2001-2002)、助理教授及癌症药理学中心实验室副主任(2002-2005)200510月至今任中国科学院上海生命科学研究院营养科学研究所研究员、博士生导师、研究组长,食品安全研究中心主任(2007-),国家卫生计生委食品安全风险评估重点实验室副主任(2012-)。长期从事营养和食品安全基础和应用研究,在PNASCancer   ResJBCOncogeneClin Cancer Res等国际杂志发表学术论文90余篇,申请国内外专利16项(其中授权5项)。任《Current Cancer Drug Targets》、《Drug Discoveries &Therapeutics》、《Acta Pharmacologica Sinica》、《中华医学杂志》、《中华预防医学杂志》、《食品安全质量检测学报》等杂志编委。现任国务院食品安全委员会专家委员会委员第一届食品安全国家标准审评委员会委员、微生物分委员会主任委员,国家科学技术奖评审专家,国家自然基金委医学部第十四届专家评审组成员,国家食品和药品监督管理局保健食品和新药审评专家、餐饮服务食品安全专家,国家卫生和计划生育委员会食品安全审评专家及新资源食品评审专家,上海市第一届食品安全风险评估专家委员会及地方标准审评委员会委员,上海市流通环节食品安全专家咨询组成员,上海市环境诱变剂学会专家委员会委员。目前承担科技部国家科技支撑计划,国家自然科学基金委杰出青年基金、重大研究计划、面上项目,上海市科委重点、重大攻关等多个项目。2006年入选上海市“浦江人才计划”,2007年入选中国科学院“百人计划”,2011年国家杰出青年科学基金获得者,2011年被评为上海市科技系统三八红旗手,2012年入选上海市优秀学术带头人。研究领域:1)发现肿瘤人群易感标志物和诊断治疗新靶点,研究靶点功能及其分子调控和信号转导,探索以膳食营养素、天然植物活性成份、化学小分子探针等靶向干预和治疗肿瘤的新机制和新方法;2)营养成分安全性评价及毒理学研究,营养素和营养素物质的安全剂量,过量时的毒理作用以及机制,食物中有毒有害物质代谢途径和致病机理,食品安全风险评估、预防控制和检测新技术研究。

发表论文清单:

1.  Li JQ, Ba Q, Yin J, WuSJ, Xu SC, Li JY, Zhang W, Wang H. (2013). Surface Display of RecombinantDrosophila melanogaster Acetylcholinesterase for Detection of OrganicPhosphorus and Carbamate Pesticides. PLoS ONE (in press).

2.  Liu Y, Li C, Chen P, LiX, Li M, Guo H, Li J, Chu R, Wang H. (2013). Polymorphisms in the vitamin Dreceptor (VDR) and the risk of ovarian cancer: a meta-analysis. PLoS ONE. Jun24;8(6):e66716.

3.  Li M, Chen PZ, Yue QX,Li JQ, Chu RA, Zhang W, Wang H. (2013). Pungent ginger components modulateshuman cytochrome P450 enzymes in vitro. Acta Pharmacol Sin. Jun 17.

4.  Ba Q, Duan J, Tian JQ,Wang ZL, Chen T, Li XG, Chen PZ, Wu SJ, Xiang L, Li JQ, Chu RA, Wang H. (2013).Dihydroartemisinin promotes angiogenesis during the early embryonic developmentof zebrafish.Acta Pharmacol Sin. May 27.

5.  Hou W, Qin X, Zhu X, FeiM, Liu P, Liu L, Moon H, Zhang P, Greshock J, Bachman KE, Ye BC, Wang H. (2013).Zang CY. Lapatinib inhibits the growth of esophageal squamous cell carcinomaand synergistically interacts with 5-fluorouracil in patient-derived xenograftmodels. Oncol Rep. May 27.

6.  Li X, Yang X, Liu Y,Gong N, Yao W, Chen P, Qin J, Jin H, Li J, Chu R, Shan L, Zhang R, Zhang W, WangH. (2013). Japonicone A suppresses growth of Burkitt's lymphoma cells throughits effect on NF-κB. Clin Cancer Res. Jun 1;19(11):2917-2928.

7.  Li X, Chen T, Lin S,Zhao J, Chen P, Ba Q, Guo H, Liu Y, Li J, Chu R, Shan L, Zhang W, Wang H. (2013).Valeriana jatamansi Constituent IVHD-valtrate As a Novel Therapeutic Agent toHuman Ovarian Cancer: in vitro and in vivo Activities and Mechanisms. CurrCancer Drug Targets. May 1;13(4):472-83.

8.  Chen P, Li M, Gu X, LiuY, Li X, Li C, Wang Y, Xie D, Wang F, Yu C, Li J, Chen X, Chu R, Zhu J, Ou Z, WangH. (2013). Higher Blood 25(OH)D Level May Reduce the Breast Cancer Risk:Evidence from a Chinese Population Based Case-Control Study and Meta-Analysisof the Observational Studies. PLoS ONE. 8(1):e49312.

9.  Lin S, Zhang ZX, Chen T,Ye J, Dai WX, Shan L, Su J, Shen YH, Li HL, Liu RH, Xu XK, Wang H, Zhang WD. (2013).Characterization of chlorinated valepotriates from Valeriana jatamansi. Phytochemistry.Jan;85:185-93.

10.  Ba Q, Zhou N, Duan J,Chen T, Hao M, Yang X, Li J, Yin J, Chu R, Wang H. (2012). DihydroartemisininExerts Its Anticancer Activity through Depleting Cellular Iron via TransferrinReceptor-1. PLoS ONE. 7(8):e42703.

11.  Ba Q, Hao M, Huang H,Hou J, Ge S, Zhang Z, Yin J, Chu R, Jiang H, Wang F, Chen K, Liu H and Wang H. (2011).Iron deprivation suppresses hepatocellular carcinoma growth in experimentalstudies. Clin Cancer Res. Dec 15;17(24):7625-33.

12.  Chen T, Xu Y, Guo H, LiuY, Hu P, Yang X, Li X, Ge S, Velu S, Nadkarni D, Wang W, Zhang R and Wang H. (2011).Experimental therapy of ovarian cancer with synthetic Makaluvamine Analog: Invitro and in vivo anticancer activity and molecular mechanisms of action. PLoSONE. 6(6):e20729.

13.  Duan J, Ba Q, Wang Z,Hao M, Hu P, Li X, Zhang D, Zhang R and Wang H. (2011). Knockdown of RibosomalProtein S7 Causes Developmental Abnormalities via p53 Dependent and IndependentPathways in Zebrafish. Int J Biochem Cell Biol. Aug;43(8):1218-27.

14.  Guo D, Chen T, Ye D, Xuj, Jiang H, Chen K, Wang H and Liu H. (2011). Cell-permeableIminocoumarine-based Fluorescent Dyes for Mitochondria. Org Lett. Jun3;13(11):2884-7.

15.  Li M, Zhou Y, Chen P,Yang H, Yuan X, Tajima K, Cao J and Wang H. (2011). Genetic Variants onChromosome 8q24 and Colorectal Neoplasia Risk: A Case-control Study in Chinaand a Meta-analysis of the Published Literature. PLoS ONE.Mar 24;6(3):e18251.

16.  Hao M, Wang W, Zhao Y,Zhang R and Wang H. (2011). Pharmacokinetics and tissue distribution of25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from  Panax ginseng, in athymic mice bearingxenografts of human pancreatic tumors. Eur J Drug Metab Pharmacokinet.Jan;35(3-4):109-13.

17.  Feng Y, Wang T, Deng Y,Yang P, Li J, Guan D, Yao F, Zhu Y, Qin Y, Wang H, Li N, Wu M,  Wang H,Wang X, Cheng S and Xie D. (2011). Sorafenibsuppresses postsurgical recurrence and metastasis of hepatocellular carcinomain an orthotopic mouse model. Hepatology. Feb;53(2):483-92.

18.  Hao M, Ba Q, Yin J, LiJ, Zhao Y and Wang H. (2011). Deglycosylated ginsenosides are more potentinducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells thanglycosylated ginsenosides. Drug Metabolism and Pharmacokinetics. 26(2):201-5.

19.  Tang H, Pang S, Wang M, Xiao X, Rong Y, Wang H, Zang YQ. (2010). TLR4 activation is required for IL-17-induced multiple tissueinflammation and wasting in mice. J Immunol. Aug 15;185(4):2563-9.

20.  Feng Y, Ding X, Chen T,Chen L, Liu F, Jia X, Luo X, Shen X, Chen K, Jiang H, Wang H, Liu H, Liu D. (2010).Design, synthesis and interaction study of quinazoline-2(1H)-thione derivativesas potential novel Bcl-xL Inhibitors. J Med Chem. May 13;53(9):3465-79.

21.  Liang J, Chen P, Hu Z,Shen H, Wang F, Chen L, Li M, Tang J, Wang H, Shen H. (2010). Genetic variantsin trinucleotide repeat-containing 9 (TNRC9) are associated with risk ofestrogen receptor positive breast cancer in a Chinese population. Breast CancerRes Treat. Nov;124(1):237-41.

22.  Lin S, Chen T, Liu XH,Shen YH, Li HL, Shan L, Liu RH, Xu XK, Zhang WD, Wang H. (2010). Iridoids andLignans from Valeriana jatamansi. J Nat Prod. Apr 23;73(4):632-8.

23.  Chen P, Hu P, Xie D, QinY, Wang F, and Wang H. (2010). Meta-analysis of Vitamin D, Calcium and thePrevention of Breast Cancer. Breast Cancer Res Treat. Jun;121(2):469-77.

24.  Chen T, Li M, Zhang R,and Wang H. (2009). Dihydroartemisinin Induces Apoptosis and Sensitizes HumanOvarian Cancer Cells to Carboplatin Therapy. J Cell Mol Med. Jul;13(7):1358-70.

25.  Lin S, Shen YH, Li HL,Yang XW, Chen T, Lu LH, Huang ZS, Liu RH, Xu XK, Zhang WD, Wang H. (2009). Acylatediridoids with cytotoxicity from Valeriana jatamansi. J Nat Prod. Apr;72(4):650-5.

26.  Chen D, Zhang J, Li M,Rayburn ER, Wang H, Zhang R. (2009). RYBP stabilizesp53 by modulating MDM2. EMBO Rep.Feb;10(2):166-72.

27.  Liang J, Chen P, Hu Z,Zhou X, Chen L, Li M, Wang Y, Tang J, Wang H and Shen H. (2008). Geneticvariants in fibroblast growth factor receptor 2 (FGFR2) contribute tosusceptibility of breast cancer in Chinese women. Carcinogenesis. Dec;29(12):2341-6.

28.  Chen P, Liang J, Wang Z,Zhou X, Chen L, Li M, Xie D, Hu Z, Shen H, and Wang H. (2008). Association ofCommon PALB2 Polymorphisms with Breast Cancer Risk: a Case-Control Study. ClinCancer Res. Sep 15; 14 (8): 5931-37.

29.  Hou J, Wang D, Zhang R,and Wang H. (2008). Experimental Therapy of Hepatoma with Artemisinin and ItsDerivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanismsof Action. Clin Cancer Res. Sep 1; 14(17):5519-30.

30.  Hao M, Zhao Y, Chen P,Huang H, Liu H, Zhang R, and Wang H. (2008). Structure-Activity Relationshipand Substrate-dependent Phenomena in Effects of Ginsenosides on Activities ofDrug-metabolizing P450 Isozymes. PLoS ONE. Jul 16;3(7):e2697.

31.  Wang W, Wang H, RayburnER, Zhao Y, Hill DL, Zhang R. (2008). 20(S)-25-methoxyl-dammarane-3β, 12β,20-triol, a novel natural product for prostate cancer: activity in vitro and invivo and mechanisms of action. Br J Cancer. Feb 26;98(4):792-802.

32.  Wang W, Rayburn ER, HaoM, Zhao Y, Hill DL, Zhang R, Wang H. (2008). Experimental Therapy of ProstateCancer with Novel Natural Product Anti-cancer Ginsenosides. Prostate. Mar6;68(8):809-819.

33.  Saif MW, Sellers S, LiM, Wang W, Cusimano L, Wang H, Zhang R. (2007). A phase I study of bi-weeklyadministration of 24-h gemcitabine followed by 24-h irinotecan in patients withsolid tumors. Cancer Chemother Pharmacol. Nov;60(6):871-82.

34.  Chen D, Zhang Z, Li M,Wang W, Li Y, Rayburn ER, Hill DL, Wang H, Zhang R. (2007). Ribosomal proteinS7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilizationof p53 protein, and activation of p53 function. Oncogene. Aug 2;26(35):5029-37.

35.  Rayburn E, Wang W, ZhangR., Wang H. (2007). Experimental therapy for colon cancer: anti-cancer effectsof TLR9 agonism, combination with other therapeutic modalities, and dependenceupon p53. Intl J Oncol. Jun;30(6):1511-9.

36.  He J, Zhou F, Shao K,Hang J, Wang H, Rayburn E, Xiao Z, Lee SW. Xue Q, Feng X, Shi S, Zhang C, ZhangS. (2007). Overexpression of Pin1 innon-small cell lung cancer (NSCLC) and its correlation with lymph nodemetastases. Lung Cancer. Apr;56(1):51-58.

37.  Wang W, Zhao Y, RayburnE, Hill DL, Wang H, Zhang R. (2007). In vitro anti-cancer activity andstructure-activity relationships of natural products isolated from fruits ofPanax ginseng. Cancer Chem Pharm. Apr;59(5):589-601.

38.  Wang H, Wang Y, RayburnER, Hill DL, Rinehart JJ, Zhang R. (2007). Dexamethasone as a chemosensitizerfor breast cancer chemotherapy: Potentiation of the antitumor activity ofadriamycin, modulation of cytokine expression, and pharmacokinetics. Intl JOncol. Apr;30(4):947-53.

39.  Wang H, Li M, Lin W,Wang W, Zhang Z, Rayburn E, Lu J, Chen D, Yue X, Shen F, Jiang F, He J, Wei W,Zeng X. Zhang R. (2007). Extracellular activity of cAMP-dependent proteinkinase (ECPKA) as a biomarker for human cancer detection: distributioncharacteristics in a normal population and cancer patients. Can EpidemBiomarker Prev. Apr;16(4):789-95.

40.  Li M, Zhang Z, Hill DL, WangH, Zhang R. (2007). Curcumin, a dietary component, has anti-cancer,chemosensitization and radiosensitization effects by down-regulating the MDM2oncogene through the PI3 kinase/mTOR/ETS2 pathway. Cancer Res. Mar1;67(5):1988-96.

41.  Zhao Y, Wang W, RayburnE, Hill DL, Wang H, Zhang R. (2007). Isolation, Structural Determination, andEvaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β,20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng. MedChem. 3:51-60.

42.  Rayburn E, Wang W, ZhangZ, Li M, Zhang R, Wang H. (2006). Experimental therapy of prostate cancer withan immunomodulatory oligonucleotide: effects on tumor growth, apoptosis,proliferation, and potentiation of chemotherapy. Prostate. Nov1;66(15):1653-63.

43.  Wang Z, Wang H, Rhie JK,Covey JM, Liang P, Wang S, Wang C, Hu Y, Prasad G, Nan L, Hill DL, Zhang R. (2006).Determination of desoxyepothilone B in nude mice plasma by liquid-liquidextraction and reversed-phase high-performance liquid chromatography. J PharmBiomed Anal. Sep 18; 42(2):272-6.

44.  LaCasse EC, Cherton-HorvatGG, Hewitt KE, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, AgrawalS, Gillard JW, Durkin JP. (2006). Preclinical characterization ofAEG35156/GEM640, a second generation antisense oligonucleotide targeting XIAP. ClinCancer Res. Sep 1;12(17):5231-41.

45.  Wang H, Rayburn E, WangW, Kandimalla ER, Agrawal S, Zhang R. (2006). Immunomodulatory oligonucleotidesas novel therapy for breast cancer: pharmacokinetics, in vitro and in vivoanti-cancer activity and potentiation of antibody therapy. Mol Cancer Ther. Aug;5(8):2106-14.

46.  Li M, Wang H, Hill DL,Stinson S, Veley K, Grossi I, Peggins J, Covey JM, Zhang R. (2006). Preclinicalpharmacology of the novel antitumor agent adaphostin, a tyrphostin analog thatinhibits bcr/abl. Cancer Chemother Pharm. 57(5):607-614.

47.  Wang H, Rayburn E, WangW, Kandimalla ER, Agrawal S, Zhang R. (2006). Chemotherapy andchemosensitization of non-small cell lung cancer with a novel immunomodulatoryoligonucleotide targeting TLR9. Mol Cancer Ther. 5(6):1585-92.

48.  Zhang Z, Wang H, Li M, Agrawal S, Zhang R. (2005).Stabilization of E2F1 proteinby MDM2 through the E2F1ubiquitination pathway. Oncogene. Nov 3;24(48):7238-47.

49.  Zhang Z, Wang H, Li M, Rayburn E, Agrawal S, Zhang R. (2005).Novel MDM2 p53-independent functions identified through RNA silencingtechnologies. Ann N Y Acad Sci. Nov;1058:205-14.

50.  Li M, Zhang Z, Hill D, Chen X, Wang H, Zhang R. (2005).Genistein, a dietary isoflavone, down-regulates the MDM2 oncogene at both transcriptionaland posttranslational levels. Cancer Res. Sep 15;65(18):8200-8.

51.  Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H. (2005).Oncogenes as novel targets for cancer Therapy (part I): Growth factors andprotein tyrosine kinases. Am J Pharmacogenomics. 5(3):173-90.

52.  Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H. (2005).Oncogenes as novel targets for cancer therapy (part II): Intermediate signalingmolecules. Am J Pharmacogenomics. 5(4):247-57.

53.  Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H. (2005).Oncogenes as novel targets for cancer therapy ((Part III): Transcription. Am JPharmacogenomics. 5(5):327-38.

54.  Zhang Z, Li M, Rayburn E, Hill DL, Zhang R, Wang H. (2005).Oncogenes as novel targets for cancer therapy (Part IV): Regulators of the cellcycle, DNA damage repair and apoptosis. Am J Pharmacogenomics. 5(6):397-407.

55.  Wang H, Rayburn E, Zhang R. (2005). Syntheticoligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpGODNs) and modified analogs as novel anti-cancer therapeutics. Curr Pharm Des.Aug;11(22):2889-907.

56.  Wang H, Li M, Rhie JK, Hockenbery DM, Covey JM, Zhang R,Hill DL. (2005). Preclinical pharmacology of 2-Methoxyantimycin A compounds asnovel antitumor agents. Cancer Chemother Pharm. May 10;56(3):291-8.

57.  Wang H, Wang Z, Wang S, Li M, Nan L, Rhie JK, Covey JM,Zhang R, Hill DL. (2005). Preclinical pharmacology of Epothilone D, a noveltubulin-stabilizing antitumor agent. Cancer Chemother Pharm. May3;56(3):255-60.

58.  Posey JA, Wang H, Hamilton J, Delgrosso A, Zhang R, FredaT, Zamboni WC. (2005). Phase-I dose escalation and sequencing study ofdocetaxel and continuous infusion topotecan in patients with advancedmalignancies. Cancer Chemother Pharmacol. Apr;56(2):182-8.

59.  Zhang R, Wang H, Agrawal S. (2005). Novel antisenseanti-MDM2 mixed-backbone oligonucleotides: Proof of principle, in vitro and invivo activities, and Mechanisms. Curr Cancer Drug Targets. Feb;5(4):43-50.

60.  Rayburn E, Zhang R, He J, Wang H. (2005). MDM2 and humanmalignancies: Expression, clinical pathology, prognostic markers, andimplications for chemotherapy. Curr Cancer Drug Targets. Feb;5(1):27-42.

61.  Rayburn E, Wang H, He J, Zhang R. (2005). RNA silencingtechnologies in drug discovery and target validation. Letters in Drug Designand Discovery. Feb;2(1):1-18.

62.  Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, ParkJK, Wang H, Peng Y, Jiang W, He TC. (2004). Wnt/beta-catenin signaling pathwayas a novel cancer drug target. Curr Cancer Drug Targets. Dec;4(8):653-71.

63.  Wang H, Li M, Rinehart JJ, Zhang R. (2004). Dexamethasoneas a chemoprotectant in cancer chemotherapy: Hematoprotective effects andaltered pharmacokinetics and tissue distribution of carboplatin andgemcitabine. Cancer Chemother Pharm. Jun;53(6):459-67.

64.  Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. (2004).MDM2 is a negative regulator of p21(WAF1/CIP1), independent of p53. J Biol Chem.Apr;279(6):16000-6.

65.  Wang H, Li M, Rinehart JJ, Zhang R. (2004). Pretreatmentwith Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabinein Mice Bearing Human Cancer Xenografts: in vivo activity, pharmacokinetics andclinical implications for cancer chemotherapy. Clin Cancer Res. Mar;10(5):1633-44.

66.  Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner J, AgrawalS, Zhang R. (2004). Radiosensitization by antisense anti-MDM2 mixed-backboneoligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res.Feb 15;10(4):1263-73.

67.  Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. (2003).Chemosensitization and radiosensitization of human cancer by antisenseAnti-MDM2 Oligonucleotides: in vitro and in vivo activities and mechanisms. AnnN Y Acad Sci. Dec;1002:217-35.

68.  Zhang Z, Li M, Wang H, Agrawal S, Zhang R. (2003).Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects onproliferation, apoptosis, multiple gene expression, and chemotherapy. Proc NatlAcad Sci U S A. Sep 30;100(20):11636-41.

69.  Kandimalla ER, Bhagat L, Wang D, Yu D, Zhu FG, Tang J, WangH, Huang P, Zhang R, Agrawal S. (2003). Divergent synthetic nucleotide motifrecognition pattern: design and development of potent immunomodulatoryoligodeoxyribonucleotide agents with distinct cytokine induction profiles. NucleicAcids Res. May 1;31(9):2393-400.

70.  Wang H, Yu D, Agrawal S, Zhang R. (2003). Experimentaltherapy of human prostate cancer by inhibiting MDM2 expression with novelmixed-backbone antisense oligonucleotides: in vitro and in vivo activities andmechanisms. Prostate. Feb 15;54(3):194-205.

71.  Bhagat L, Zhu FG, Yu D, Tang J, Wang H, Kandimalla ER,Zhang R, Agrawal S. (2003). CpG penta- and hexadeoxyribonucleotides as potentimmunomodulatory agents. Biochem Biophys Res Comm. Jan 24;300(4):853-61.

72.  Yu D, Zhu F, Bhagat L, Wang H, Kandimalla ER, Zhang R,Agrawal S. (2002). Potent CpG oligonucleotides containing phosphodiesterlinkages: in vitro and in vivo immunostimulatory properties. Biochem BiophysRes Comm. Sep;297(1):83-90.

73.  Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, AgrawalS, Zhang R. (2002). Antisense oligonucleotide targeted to RIalpha subunit ofcAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness ofcancer chemotherapeutic agent irinotecan in nude mice bearing human cancerxenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. IntJ Oncol. Jul;21(1):73-80.

74.  Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie JK, ZhangR, Hill DL. (2002). Radiolabeled 2'-fluorodeoxyuracil-beta-D-arabinofuranoside(FAU) and 2'-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) astumor-imaging agents in mice. Cancer Chemother Pharmacol. May;49(5):419-24.

75.  Wang H, Wang S, Nan L, Yu D, Agrawal S, Zhang R. (2002).Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeuticefficacy of topoisomerase I inhibitor irinotecan in nude mice bearing humancancer xenografts: In vivo activity and mechanisms. Int J Oncol. Apr;20(4):745-52.

76.  Prasad G, Wang H, Agrawal S, Zhang R. (2002). Antisenseoligonucleotides targeted to MDM2 oncogene as a novel approach to the treatmentof glioblastoma multiforme. Anticancer Res. Apr;22:107-16.

77.  Wang H, Nan L, Yu D, Lindsey JR, Agrawal S, Zhang R. (2002).Anti-tumor efficacy of a novel antisense anti-mdm2 mixed-backboneoligonucleotide in human colon cancer models: p53-dependent and p53-independentmechanisms. Mol Med. Apr;8(4):185-99.

78.  Wang H, Nan L, Yu D, Agrawal S, Zhang R. (2001).Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to humanbreast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res.Nov;7(11):3613-24.

79.  Zhang R, Wang H. (2000). MDM2 Oncogene as a novel targetfor human cancer therapy. Curr Pharm Des. Mar;6(4):393-416.

80.  Wang H, Zeng X, Oliver P, Le LP, Chen J, Chen L, Zhou W,Agrawal S, Zhang R. (1999). MDM2 oncogene as a target for cancer therapy: Anantisense approach. Int J Oncol. 15(4):653-60.

81.  Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. (1999).Antitumor activity and pharmacokinetics of a mixed-backbone antisenseoligonucleotide targeted to the RIa subunit of protein kinase A after oraladministration. Proc Natl Acad Sci USA. 96(24):13989-94.


  • Copyright©国家食品安全风险评估中心 版权所有 京ICP备12013786号
  • 联系地址:北京市朝阳区广渠路37号院2号楼 电话:52165518 传真:52165519